drugset / Trial / NCT04372927
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment with durvalumab, is it possible to avoid mediastinal radiation to decrease side effects, without decreasing cancer control?
Timeline
- Start
- 2021-12-10
- Primary completion
- 2022-04-23
- Completion
- 2022-04-23
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |